Gilead won't acquire checkpoint oncology biotech Tizona
Gilead has now passed on two biotech buyout options that it forged in the summer of 2020.
The large drugmaker will not acquire Tizona Therapeutics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
